Monte Rosa Will Present MRT-8102 Clinical Study Results
Boston-based Monte Rosa Therapeutics will share GFORCE-1 study data during an upcoming conference call.
Updated on Sept. 30, 2026 in Biotech
Monte Rosa Therapeutics will present clinical results from its GFORCE-1 Phase 1 study on October 1, 2026. The presentation will detail safety and activity data for the molecular glue degrader MRT-8102 after a 4-week treatment duration.
Why it matters
The study evaluates MRT-8102 for its ability to modulate pathogenic drivers in patients with elevated cardiovascular disease risk. This data release provides insight into the potential of the NEK7-directed therapy to address atherosclerotic cardiovascular disease.
The GFORCE-1 study evaluates MRT-8102, a NEK7-directed molecular glue degrader developed via the company's proprietary QuEEN discovery engine. This platform integrates AI-guided chemistry, structural biology, and proteomics to target pathogenic drivers.
The players
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a Boston-based clinical-stage biotechnology company that specializes in molecular glue degraders.
The details
Monte Rosa Therapeutics will review findings from the 4-week study during a live conference call and webcast. The company focuses on utilizing its QuEEN engine to identify degraders that target specific drivers of atherosclerotic cardiovascular disease.
Timeline
October 1, 2026, 8:00 a.m. ET: Conference call and webcast presentation.
30 days post-presentation: Availability of the archived webcast.
The Tech Race
The development of MRT-8102 via the QuEEN engine represents a broader industry shift toward AI-driven structural biology in drug discovery. This approach moves beyond traditional small-molecule inhibition by utilizing molecular glue degraders to address previously undruggable targets.
Investors and stakeholders can access the presentation materials via the company's investor relations portal to evaluate the trial progress. The data release offers insight into future treatment possibilities for those managing cardiovascular disease risks.
The takeaway
The GFORCE-1 study highlights the ongoing integration of AI-guided tools in developing targeted cardiovascular therapies. Researchers and observers should monitor how these 4-week trial results influence the next stages of clinical development for molecular glue degraders.
What happens next
A webcast of the presentation will be available on the company website for 30 days starting after the October 1, 2026, event.
Further reading
For more information on current developments in the sector, visit the Biotech section.
More information
To access the live webcast or archived files, visit Monte Rosa events and presentations.
